Key Takeaway: Absci has announced positive interim results from its Phase 1 HEADLINE™ trial of ABS-201, an antibody targeting the prolactin receptor. The study indicates that the medication is well tolerated, with favorable safety data across all cohorts. Additionally, the estimated half-life of ABS-201 suggests a potential dosing interval of two to three injections over six months.
Price reaction · baseline $7.41 (2026-06-23 close) · hit pre-market · 1 other ABSI headline(s) in the window, move may be shared
day 0 close
+36%
day 1
+37.8%
day 3 · peak
+53.2%
Market Sentiment Analysis
POSITIVE FACTORS
Study medication shows favorable safety data.
Well-tolerated across all cohorts.
Estimated half-life supports infrequent dosing.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+405%
120-day peak, hindsight
Typical move
13.1%
average across 4 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
ABS-201
Phase 1 · Androgenetic Alopecia (AGA)
Full Press Release Details
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose
Frequently Asked Questions
What is the purpose of the HEADLINE™ trial?
The HEADLINE™ trial is evaluating ABS-201, an antibody targeting the prolactin receptor.
How well tolerated is the study medication?
The study medication appears well tolerated with favorable safety data.
What is the estimated half-life of ABS-201?
The estimated half-life of ABS-201 is at least 65 days.
What dosing interval is suggested for ABS-201?
ABS-201 may have a dosing interval of two to three injections over six months.